Last reviewed · How we verify
Mytelase (AMBENONIUM)
Mytelase (Ambenonium) is a small molecule cholinesterase inhibitor developed by Sanofi Aventis US, targeting acetylcholinesterase to treat Myasthenia gravis. It was FDA approved in 1956 and remains off-patent with no active Orange Book patents. Mytelase works by inhibiting the breakdown of acetylcholine, a neurotransmitter that facilitates muscle contraction. As a result, it increases the concentration of acetylcholine in the synaptic cleft, leading to improved muscle strength and function in patients with Myasthenia gravis. Despite being off-patent, Mytelase is still commercially available.
At a glance
| Generic name | AMBENONIUM |
|---|---|
| Sponsor | Sanofi |
| Drug class | Cholinesterase Inhibitor |
| Target | Acetylcholinesterase |
| Modality | Small molecule |
| Therapeutic area | Neuroscience |
| Phase | FDA-approved |
| First approval | 1956 |
Approved indications
- Myasthenia gravis
Common side effects
Drug interactions
- betamethasone
- cortisone
- desoxycortone
- dexamethasone
- fludrocortisone
- hydrocortisone
- methylprednisolone
- paramethasone
- prednisolone
- prednisone
- tetracosactide
- triamcinolone
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Mytelase CI brief — competitive landscape report
- Mytelase updates RSS · CI watch RSS
- Sanofi portfolio CI